Q4 2022 Highlights Operational Highlights Financial Results • Received approval from the Japanese Pharmaceuticals and Medical † • Net sales growth : Devices Agency (PMDA) for the AGENT™ Drug Coated Balloon (DCB) in Japan to treat patients with in-stent restenosis (ISR) and coronary small • +3.7% reported, +8.7% operational*,+7.1% organic* vessel disease (SVD), with launch anticipated in the first half of this year. Y/Y • Completed enrollment in the CHAMPION-AF clinical trial, evaluating the † safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage • Earnings per share : Closure Device compared to non-vitamin K antagonist oral • As reported: $0.09 vs. $0.06 Q4:21 anticoagulants for stroke prevention in a broad population of patients with non-valvular atrial fibrillation. • Adjusted*: $0.45 vs. $0.45 Q4:21 † • Completed enrollment in this SOLIS clinical trail to assess WaveWriter • Gross margin : Spinal Cord Stimulator Systems (SCS) for the treatment of patients with • As reported: 68.8%, (10) bps Y/Y chronic low back and/or leg pain who have not undergone spinal surgery. The study met its primary endpoint; SCS demonstrated superior • Adjusted*: 70.5%, (40) bps Y/Y outcomes compared with Conventional Medical Management (CMM) † at three-month follow-up. • Operating margin : • Began enrollment in the ACURATE Prime XL Nested Registry, which is • As reported: 12.4%, +660 bps Y/Y designed to assess outcomes from patients receiving the larger ACURATE • Adjusted*: 25.7%, (50) bps Y/Y Prime™ Aortic Valve XL within the ACURATE IDE clinical study in the U.S. Also announced, at PCR London Valves, late-breaking data from the • Q1 2023 guidance vs. Q1 2022: European ACURATE neo2 Post Market Clinical Follow-up study supporting • As reported net sales growth: 3% - 5% the clinical procedural success and safety of the ACURATE neo2™ Aortic Valve System. • As reported EPS: $0.23 - $0.26 • Presented positive late-breaking data from the ELEGANCE registry at the • Organic* net sales growth: 6% - 8% 2022 VIVA conference, which highlighted that the study is currently • Adjusted EPS*: $0.42 - $0.44 exceeding its goal to increase the representation of women and underrepresented minorities in clinical trials for drug-eluting peripheral • FY 2023 guidance vs. FY 2022: therapies. • As reported net sales growth: 5% - 7% • Announced agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: • As reported EPS: $1.11 - $1.21 APEN), subject to customary closing conditions, to expand the Boston Scientific endoluminal surgery portfolio and enable a measured entry • Organic* net sales growth: 6% - 8% into the endobariatric market. • Adjusted EPS*: $1.86 - $1.93 • Announced strategic investment to acquire majority stake in Acotec † Included within Q4 results is a ($60M) unplanned reserve established in connection with the activation of the Italian Scientific Holdings Limited, a Chinese medical technology company that government payback provision, aimed at rationalizing public spending and requiring medical device companies to offers solutions designed for a variety of interventional procedures, pay back a portion of spend exceeding allocated healthcare budgets expected to close in 1H:2023, subject to customary closing conditions. 3 Q4 2022 Financial & Operational Highlights | February 1, 2023